# Clinical Trials Data KIT - Document 9

# A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

## Clinical Trial: https://clinicaltrials.gov/study/NCT01525550

"description": "EORTC QLQ-GI-NET 21 was a 21-item questionnaire. These 21 questions assesses endocrine symptoms, gastrointestinal (G.I.) symptoms, treatment related symptoms, social functioning, disease related worries, muscle/bone pain, sexual function, information/communication function and body image. Each item was answered on a 4-point scale: 1 =not at all, 2 =a little, 3 =quite a bit, 4 =very much; where higher scores indicated more severe symptoms/problems. Scores averaged, transformed to 0-100 scale; higher score=more severe symptoms.",  
 "eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization \\[WHO 2000\\] classification).\n\* Disease progression within 12 months prior to study enrollment.\n\* Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.\n\nExclusion Criteria:\n\n\* Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).\n\* Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]  
 "description": "EORTC QLQ-GI-NET 21 was a 21-item questionnaire. These 21 questions assesses endocrine symptoms, gastrointestinal (G.I.) symptoms, treatment related symptoms, social functioning, disease related worries, muscle/bone pain, sexual function, information/communication function and body image. Each item was answered on a 4-point scale: 1 =not at all, 2 =a little, 3 =quite a bit, 4 =very much; where higher scores indicated more severe symptoms/problems. Scores averaged, transformed to 0-100 scale; higher score=more severe symptoms.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention\*\* KIT gene mutations as either an inclusion or exclusion criterion. Therefore, we \*\*cannot determine\*\* eligibility based on this information alone. A patient with a KIT mutation \*might\* be eligible if they meet all other inclusion criteria and none of the exclusion criteria, but more information would be needed.